NCT05179408 Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer
| NCT ID | NCT05179408 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-12 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-01-12 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, and fear/anxiety about lung cancer, and impairments in physical and psychosocial functioning. Rehabilitation services are needed to address these survivorship challenges. This study will evaluate multi-targeted telerehabilitation with Veterans following lung cancer treatment, with goals to reduce symptom burden, improve physical and psychosocial function, and enhance health-related quality of life. This research will also develop the career of a physician researcher to acquire expertise in rehabilitation for many Veteran survivors of lung and other cancers.
Eligibility Criteria
Inclusion Criteria: * Adult Veterans with a history of stage I-III A/B lung cancer, and * Completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months Exclusion Criteria: * Adult Veterans with any comorbid conditions that preclude participation in exercise and telerehabilitation: * Orthopedic conditions (e.g., bilateral below-knee amputation), or * Severe cardiopulmonary disease (e.g., unstable arrhythmias including ventricular tachycardia, heart failure with systolic ejection fraction \< 25%, chronic hypoxemia needing \> 5 L/min oxygen supplementation at rest), or * Inability to follow directions or provide informed consent (e.g., moderate to severe dementia), or * Enrolled in hospice, or * With an estimated life expectancy of \< 6 months
Contact & Investigator
Duc M. Ha, MD MAS
PRINCIPAL INVESTIGATOR
Rocky Mountain Regional VA Medical Center, Aurora, CO
Frequently Asked Questions
Who can join the NCT05179408 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05179408 currently recruiting?
Yes, NCT05179408 is actively recruiting participants. Contact the research team at Duc.Ha@va.gov for enrollment information.
Where is the NCT05179408 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT05179408 clinical trial?
NCT05179408 is sponsored by VA Office of Research and Development. The principal investigator is Duc M. Ha, MD MAS at Rocky Mountain Regional VA Medical Center, Aurora, CO. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.